Regnan Global Equity Impact Solutions (REGIX)


Fund Description

Regnan Global Equity Impact Solutions is a high conviction, diversified, global multi-cap portfolio with a strong emphasis on driving impact through engagement. The team aim to generate long-term outperformance by investing in mission-driven companies that create value for investors by providing solutions for the growing unmet sustainability needs of society and the environment. They use the United Nations Sustainable Development Goals (SDGs) as an investment lens.

Investment Objective

The investment objective of Regnan Global Equity Impact Solutions (the "Fund") is to seek to achieve long-term capital appreciation by investing in companies that contribute solutions to addressing the world's major social and environmental challenges.

  • Tim Crockford

    Head of Equity Impact Solutions

    small image path
  • Mohsin Ahmad

    Fund Manager

    small image path
  • Maxime Le Floch


    small image path
  • Maxine Wille


    small image path

Fund details

Data as at 28 February 2023
Fund size $14.21mn
Strategy size $365.65mn ()
Fund inception date 23 August 2021
Benchmark MSCI ACWI Investable Market Index
Share classes
Institutional (Launch date) 23-August-2021
Minimum investment
Institutional $1,000,000
Fund codes
Fund Ticker Share Class Fund Number CUSIP
REGIX Institutional 689 46653M716
Fees and Expenses
Fund Ticker Share Class Net Expense Ratio* Gross Expense Ratio*
REGIX Institutional 0.89% 7.10%

JOHCM (USA) Inc. (the "Adviser") has contractually agreed to waive fees and reimburse expenses to the extent that Total Annual Operating Expenses (excluding brokerage costs, interest, taxes, dividends, litigation and indemnification expenses, expenses associated with investment in underlying investment companies, and extraordinary expenses) exceed 0.89%, 0.99%, 1.14% and 0.89% for Institutional Shares, Advisor Shares, Investor Shares and Class Z Shares, respectively, until January 28, 2024.


Investment Advisor JOHCM (USA) Inc.
Transfer Agent Northern Trust
Custodian Northern Trust

Investment Background

Data as at 28 February 2023

Strategy Highlights

As at 31 December 2022

Global equity markets finished the fourth quarter in positive territory, with developed markets outperforming emerging markets. The Fed’s November CPI announcement reinforced the emerging market narrative that inflation has peaked, with the smallest annual increase in inflation since December 2021 at 7.1%.

The strategy outperformed the MSCI ACWI IMI reference index during the period. There was continued strong fundamental momentum for the majority of names in the portfolio, making the holdings even more attractive going into 2023.

The largest contributors were portfolio holdings in healthcare and industrials, where portfolio holdings have continued to see substantial earnings upgrades, driving a de-rating to valuation levels that the team believes fail to take into account their continued and sustainable growth potential; this is true not just in the long-term, but also expected to persist over the coming year, when the team expect that the average listed-company will see continuing downwards revisions of the market’s earnings expectations.

Novo Nordisk was the largest positive contributor during the quarter, delivering another strong set of results with an upgrade in guidance and confirmation of a relaunch of the supply of Wegovy by the end of the year, a first of its kind once-weekly injectable used as a treatment for chronic obesity. Befesa also performed strongly and announced an ambitious growth plan at its Capital Markets Day in November, which included a focus on opportunities in its home market of Europe, driven by the transition to electric vehicles and light weighting of vehicles which have increased demand for aluminium.

Yduqs was a prominent detractor during the fourth quarter. While the Brazilian presidential election result is expected to be broadly supportive of the education sector, this is yet to be reflected in an uptick of admissions. Following strong performance earlier in the year, Alfen also detracted. While the EV charging business continued to deliver strong growth, management guidance pointed to a normalisation of growth rates in Q4, driven by the destocking of customer inventories built up earlier in the year following covid related supply chain disruptions. Despite this, we remain positive on Alfen’s growth potential, given its position as one of Europe’s leading EV charging equipment suppliers with the capacity to grow ahead of the market.

During the quarter, we took the opportunity to add Stevanato to the portfolio, a global leader in producing glass vials for aseptic manufacturing for pharmaceuticals, with its presterilised containment solutions playing a critical role in patient safety while also enabling greater automation, reducing time to market and cost of ownership.

Looking across the investment universe as the year ended, valuations in the US remain elevated relative to their counterparts in similar industries that are listed outside of the US. While we believe we are likely to see disinflation and, in some economies, a corporate earnings recession ensue throughout 2023, this is unlikely to drive policy rates back down to the pandemic levels that are needed to justify US mega-cap growth valuations, particularly if their growth rates continue to moderate.

Meanwhile, our portfolio has experienced a ‘valuation reset’, as many constituents’ earnings have continued to be revised upwards over the year. With over a third of the portfolio in the SMID-cap healthcare growth category (predominately life sciences businesses that have a structural growth tailwind, which include Sartorius Stedim, Abcam, Lonza, Carl Zeiss Meditec, Qiagen, Agilent, and our most recent addition, Stevanato), we feel confident that their growth trajectory will remain intact, even if macroeconomics conditions toughen as the year rolls on.

We enter the new year optimistic about the continued positive development of the portfolio’s growth, despite the uncertainty within markets and across economies.

We expect portfolio company earnings to be resilient relative to the rest of the market, whether the expected recession does materialise as a mild or more drawn out slow down, as the life sciences and health technology companies listed above are expected to have lower economic sensitivity and are driven by a tailwind that we expect to persist for many years to come.

Total Return (%)

Data as at February 28, 2023
  1 Month Total Return 3 Month Total Return YTD Total Return 1 Year Total Return Cumulative Since Inception
Institutional Net -2.93 0.09 3.11 -9.36 -27.03
Benchmark -2.87 0.39 4.30 -8.09 -11.78

Monthly returns (%)

Data as at 28 February 2023
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Annual
Fund 2021 0.30 -8.04 3.97 -4.04 2.61 -5.58
Benchmark 2021 1.67 -3.99 4.86 -2.68 3.97
Benchmark 2022 -5.19 -2.29 2.04 -7.94 0.06 -8.63 7.14 -3.55 -9.65 6.15 7.61 -3.83 -18.40
Fund 2022 -12.81 -2.22 1.64 -10.07 1.69 -9.99 10.39 -6.22 -10.09 8.96 6.77 -2.93 -25.04
Fund 2023 6.22 -2.93 3.11
Benchmark 2023 7.28 -2.87 4.30

Top 10 holdings and active weights

Data as at 28 February 2023
Top 10 holdings
Ansys 5.54%
Agilent 5.28%
Qiagen 5.13%
Novo Nordisk 5.05%
Bank Rakyat Indonesia 4.81%
ATS Automation Tooling Systems 4.77%
Lonza 4.73%
Horiba 4.53%
Sartorius 4.52%
Xylem 4.43%
Top 10 active weights
Ansys +5.50%
Agilent +5.22%
Qiagen +5.12%
Bank Rakyat Indonesia +4.77%
ATS Automation Tooling Systems +4.77%
Novo Nordisk +4.70%
Lonza +4.67%
Horiba +4.53%
Sartorius +4.51%
Xylem +4.40%

Regional / Country breakdown

Data as at 28 February 2023
Portfolio Benchmark Relative
Brazil 4.93% 0.55% 4.37%
Canada 4.77% 3.1% 1.67%
Denmark 9.02% 0.74% 8.27%
France 6.85% 2.96% 3.89%
Germany 15.74% 2.11% 13.63%
Indonesia 4.81% 0.22% 4.58%
Japan 4.53% 5.97% -1.44%
Switzerland 4.73% 2.42% 2.31%
United Kingdom 6.43% 4.03% 2.39%
United States 26.10% 59.28% -33.18%
Cash 2.35% 0% 2.35%

Sector breakdown

Data as at 28 February 2023
Portfolio Benchmark Relative
Health Care 35.49% 12.02% 23.50%
Industrials 25.59% 11.28% 14.30%
Information Technology 14.27% 20.06% -5.80%
Consumer Discretionary 7.08% 11.23% -4.10%
Financials 6.21% 15.23% -9.00%
Materials 5.01% 5.37% -0.40%
Utilities 3.96% 2.88% 1.10%
Communication Services 0.00% 6.51% -6.50%
Consumer Staples 0.00% 7.05% -7.10%
Energy 0.00% 5.09% -5.10%
Real Estate 0.00% 3.23% -3.20%
Cash 2.35% 0.00% 2.35%

Market cap breakdown

Data as at 28 February 2023
Portfolio Benchmark Relative
Large 36.35% 73.07% -3.99%
Mid 58.26% 25.38% 32.88%
Small 2.82% 1.56% 1.26%


As at noon Share class Currency CUSIP Number NAV Change Change % Previous
JOHCM International Select Fund 29/03/2023 Institutional USD 46653M849 21.29 0.19 0.90% 21.10
Investor USD 46653M823 21.34 0.19 0.90% 21.15
JOHCM Emerging Markets Opportunities Fund 29/03/2023 Advisor USD 46653M203 10.70 0.17 1.61% 10.53
Institutional USD 46653M104 10.73 0.17 1.61% 10.56
Investor USD 46653M302 10.69 0.16 1.52% 10.53
JOHCM Global Select Fund 29/03/2023 Advisor USD 46653M807 12.49 0.12 0.97% 12.37
Institutional USD 46653M708 12.53 0.12 0.97% 12.41
JOHCM Emerging Markets Small-Mid Cap Equity Fund 29/03/2023 Advisor USD 46653M500 11.57 0.11 0.96% 11.46
Institutional USD 46653M401 11.58 0.11 0.96% 11.47
JOHCM Global Income Builder Fund 29/03/2023 Advisor USD 46653M799 9.73 0.00 0.00% 9.73
Institutional USD 46653M815 9.73 0.00 0.00% 9.73
Investor USD 46653M781 9.73 0.00 0.00% 9.73
JOHCM International Opportunities Fund 29/03/2023 Institutional USD 46653M872 10.59 0.12 1.15% 10.47
JOHCM Credit Income Fund 29/03/2023 Institutional USD 46653M740 8.97 0.00 0.00% 8.97
Regnan Global Equity Impact Solutions 29/03/2023 Institutional USD 46653M716 7.26 0.06 0.83% 7.20
TSW Large Cap Value Fund 29/03/2023 Institutional USD 46653M641 12.44 0.11 0.89% 12.33
TSW High Yield Bond Fund 29/03/2023 Institutional USD 46653M658 8.67 0.03 0.35% 8.64
10 Nov 2022

Regnan Global Equity Impact Solutions Strategy

Quarterly Impact Report Q2 2022

21 Feb 2022

Q4 Quarterly Impact Report - Regnan Global Equity Impact Solutions

The latest quarterly impact report features thematic research on Liquid Biopsy – a promising alternative to traditional tissue-based biopsies.

No Data


An investor should consider the Fund’s investment objectives, risks, and charges and expenses carefully before investing or sending any money. This and other important information about the Funds can be found in the Fund’s(s) prospectus or summary prospectus which can be obtained at or by calling 866-260-9549 or 312-557-5913. Please read the prospectus or summary prospectus carefully before investing. The JOHCM Funds are advised by J O Hambro Capital Management Limited and distributed through Foreside Financial Services, LLC, member FINRA. The JOHCM Funds are not FDIC-insured, may lose value, and have no bank guarantee.


The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested. Investing in companies in emerging markets involves higher risk than investing in established economies or securities markets. Emerging Markets may have less stable legal and political systems, which could affect the safe-keeping or value of assets. The Fund’s investment include shares in small-cap companies and these tend to be traded less frequently and in lower volumes than larger companies making them potentially less liquid and more volatile. The Fund intends to invest its assets in companies that meet its impact investing criteria pursuant to the Regnan Taxonomy. This may affect the Fund’s exposure to certain companies or industries and the Fund will forego certain investment opportunities. The Fund’s results may be lower than other funds that do not seek to invest in companies based on expected environmental or societal impact outcomes. Successful application of the Fund’s impact investing strategy will depend on its portfolio managers’ ability to identify and analyze a company’s impact, and there can be no assurance that the strategy or techniques employed will be successful.

For a better experience, we recommend viewing this website in landscape orientation.